Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer

NCT00433095 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Carcinoma Breast Stage IV

Interventions

DRUG: Navelbine
DRUG: Herceptin
DRUG: Navelbine (oraly)

Sponsor

Ludwig-Maximilians - University of Munich

Collaborators

[object Object]